TB/HIV and other immunosuppressive states
|
|
- Brittney Hodges
- 5 years ago
- Views:
Transcription
1 TB/HIV and other immunosuppressive states Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease TB Clinical Intensive Seattle, WA June 14 15, 2018 Roadmap for today s talk TB in people living with HIV (PLHIV) Risk of LTBI >TB Clinical manifestations TB treatment (ART/TB medication interactions) Immune reconstitution inflammatory syndrome (IRIS) LTBI treatment TB and other immunosuppressive states Solid organ (and hematopoietic stem cell) transplant Immunosuppressive/TB medication interactions TB and biologics (TNF alpha inhibitors) 1
2 Latent TB (LTBI) and active TB Small, NEJM 2001 Latent TB (LTBI) and active TB HIV 10% over lifetime greatest risk in 1st 2 years Small, NEJM
3 Latent TB (LTBI) and active TB HIV 10% over lifetime greatest risk in 1st 2 years HIV+ 10% per year Small, NEJM 2001 HIV kills TB specific CD4 cells Impairs macrophage activation Fewer lung homing CD4 cells Defective granuloma formation Loss of control of infection Geldmacher, Curr Opin HIV AIDS,
4 MTb infec on TB disease Lawn Clin Dev Immunology 2011 MTb infec on TB disease ART (+ TPT) Although ART significantly decreases TB risk, still much higher than among HIV Lawn, Clin Dev Immunology
5 Clinical Manifestations of TB in HIV+ Influenced by degree of immunosuppression Most still present with pulmonary disease Upper lobe fibronodular infiltrates +/ cavitation Advanced HIV (CD4 < 200) Can have pulmonary TB (+ AFB/cx) w/ nml CXR Often smear negative >paucibacillary Extrapulmonary/disseminated disease common Lymphadenitis, pleuritic, pericarditis, meningitis, sepsis Important to evaluate for PTB in HIV+ with EPTB DHHS 2017 Question 1 Which of the following is true? A. HIV significantly increases the risk of progression from LTBI to TB B. ART significantly decreases the risk of TB among HIV+ C. Once on ART, risk of TB among HIV+ is similar to HIV D. Most common presentation of TB among HIV+ is extrapulmonary E. A & B F. C & D 5
6 TB treatment in HIV+ Anti TB regimen generally the same for non HIV Initial phase: INH, RIF, PZA, EMB x 2 months Continuation phase: INH, RIF x 4 months Extended to 7 months if initial CXR + cavitation & Cx + at end of 2 months of initial phase Important exceptions for HIV+: Initial phase: INH, RIF, PZA, EMB given daily Continuation phase: INH, RIF given daily (or 3 x week) If no ART during TB tx: extend to 7 months Culture negative pulm TB: 6 months total treatment (vs. 4 months HIV ) ATS, CDC, IDSA CID 2016 DHHS 2017 TB treatment in HIV+ Drug(s) Duration Interval Comment Initial phase INH, RIF, PZA, EMB 2 months Daily Recommended Continuation phase INH/RIF 4 months Daily Recommended INH/RIF 4 months 3 x week Alternative For HIV+ both initial phase and INH/RIF 4 continuous months Twice phase weekly are given daily Not recommended for HIV+ INH/RPT 4 months Once weekly Contraindicated ATS, CDC, IDSA CID 2016 DHHS
7 Basic Principles in ART and TB treatment Rifamycin based TB treatment is cornerstone of effective TB treatment Efavirenz based ART preferred Most drug drug interactions due to Rifampin Potent inducer of P450 enzyme 3A sometimes requires ART dose adjust (typically dose) Rifabutin less potent inducer Sometimes requires rifabutin dose adjust ( or dose) Important: if ART dc d, rifabutin may be subtherapeutic DHHS 2017 CDC 2013 ATS, CDC, IDSA CID 2016 Timing of ART and TB treatment ART is recommended for all HIV+ with TB For ART naïve CD4 < 50 start ART within 2 weeks CD4 > 50 start by 8 12 weeks Exception: TB meningitis start > 8 weeks (to reduce risk of IRIS) If already on ART, continue ART May require medication adjustment DHHS 2017 ATS, CDC, IDSA CID
8 ARV ARV dose change RIF dose change Comments NNRTIs Efavirenz None; some 800mg if >50kg No change Preferred Regimen (still!) Nevirapine Rilpivirine Etravirine NRTIs Tenofovir disoproxil fumarate (TDF) Tenofovir alafenamide (TAF) ART and RIF recommended dose adjustments lead in dose 200 mg No change twice daily, continue as maintenance dose Contraindicated None None Preferred Unknown Avoid lead in 200mg once daily, assoc w/ virologic failure Consider therapeutic drug monitoring. Rarely used in US Significant decrease in Rilpivirine TAF concentration decreased in healthy volunteers (but intracellular concentrations still higher than TDF) CROI 2018 RIF decreases NNRTI (and some NRTI) levels DHHS 2017 CDC 2013 ATS, CDC, IDSA CID 2016 CROI 2018 ART and RIF recommended dose adjustments (cont.) Integrase inhibitors Raltegravir Raltegravir to 800 mg twice daily Dolutegravir Dolutegravir to 50 mg twice daily ARV dose change RIF dose change Comments No change No change Raltegravir trough concentrations still decreased, follow VL carefully follow VL carefully Bictegravir Bictegravir should not be used together Decrease in Bictegravir even when given BID (Custodia, CROI 2018) Elvitegravir, Stribild or Genvoya and rifampin should cobicistat, TDF or TAF, not be used together and emtricitabine (Stribild or Genvoya) CCR 5 receptor antagonists Maraviroc Maraviroc to 600 No change mg twice daily Marked decrease in elvitegravir and cobicistat concentrations predicted based on metabolic pathways of these drugs Use with caution, as there is no reported clinical experience with increased dose of maraviroc with rifampin RIF decreases INSTI levels DHHS 2017 CDC 2013 ATS, CDC, IDSA CID
9 ART and RIF recommended dose adjustments (cont.) ARV dose change RIF dose change Comments Protease inhibitors Lopinavir/ritonavir (Kaletra ) Super boosted lopinavir/ritonavir (Kaletra ) Atazanavir (single agent or ritonavir boosted) Darunavir/r Fosamprenavir/r Saquinavir/r Lopinavir 800 mg plus No change ritonavir 200 mg twice daily (double dose) Lopinavir 400 mg plus No change ritonavir 400 mg twice daily (super boosting) Contraindicated Hepatotoxicity in healthy volunteers Better tolerated among HIV+ already on LPV/r Hepatotoxicity in healthy volunteers Significant decrease in PIs, Increased PI doses associated +/ hepatotoxicity For PIs RFB preferred DHHS 2017 CDC 2013 ATS, CDC, IDSA CID 2016 ARV ARV dose change RFB dose change Comments NNRTIs Efavirenz No change 600 mg (daily or RIF preferred thrice weekly) Nevirapine No change No change Etravirine No change No change Conc of both decreased Rilpivirine Contraindicated Significant decrease in Rilpivirine Protease inhibitors Atazanavir (single agent or ritonavir boosted) ART and RFB recommended dose adjustments No change 150 mg daily No pub clinical experience Monitor closely for potential rifabutin toxicity uveitis, hepatotoxicity, and neutropenia Darunavir/r Fosamprenavir/r Saquinavir/r Lopinavir/ritonavir (Kaletra ) No change 150 mg daily Monitor closely for potential rifabutin toxicity uveitis, hepatotoxicity, and neutropenia No change 150 mg daily Hepatotoxicity in healthy volunteers Better tolerated among HIV+ already on LPV/r RFB levels decreased with EFV, increased with PIs DHHS 2017 CDC 2013 ATS, CDC, IDSA CID
10 ART and RFB recommended dose adjustments (cont.) ARV dose change RFB dose change Comments Integrase inhibitors Raltegravir No change No change RAL conc Dolutegravir No change No change DOL conc Elvitegravir, cobicistat, tenofovir, and emtricitabine (Stribild ) CCR 5 receptor antagonists Stribild (or Genvoya) and rifabutin should not be used together Marked elvitegravir, cobicistat conc Marked rifabutin Maraviroc No change No change No clinical experience; a significant interaction is unlikely, but this has not yet been studied INSTI levels increased with RFB DHHS 2017 CDC 2013 ATS, CDC, IDSA CID 2016 ART and TB treatment: Overlapping toxicities Adverse effect ART Anti TB therapy Gastrointestinal AZT, ddi, PIs R,I,P, ethionamide, PAS, Clofazamine, linezolid Hepatotoxicity NVP, EFV, PIs, NRTIs R,I,P, ethionamide, quinolones, PAS Neuropathy D4T, ddi I, ethionamide, cycloserine, linezolid Renal dysfunction TDF Aminoglycosides and capreomycin Neuropsychiatric Upon EFVre challenge Cycloserine, >90% patients ethionamide, quinolones, Rash INH tolerate medications without a NVP, EFV, ABC R,I,P,E, streptomycin, quinolones, PSA, recurrence of the adverse clofzamine effect Cytopenia AZT, 3TC R,I, linezolid, rifabutin Cardiac conduction PIs Bedaquiline, quinolone, clofazamine Pancreatitis D4T, ddi Linezolid Lactic acidosis D4T, ddi Linezolid ATS, Am J Respir Crit Care Med, 2006 Lawn, BMC Medicine,
11 Question 2 Which of the following are true in the management of TB in an HIV+ individual? A. Rifamycins should be avoided due to multiple ART and anti TB medication interactions B. In an ART naïve HIV+ patient, ART initiation should be deferred until after TB treatment is completed to avoid drug interactions C. Integrase inhibitors require dose adjustment (increase) when co administered with rifampin D. Rifampin requires dose adjustment when co administered with Efavirenz Immune Reconstitution Inflammatory Syndrome: IRIS IRIS: collection of inflammatory disorders Paradoxical worsening of preexisting infectious processes Assoc w/ immune recovery following ART initiation Risk Factors: CD4 and VL pre ART, short time between TB tx and ART initiation, but TB IRIS can occur at CD4 >200 Meintjes, Lancet ID,
12 Immune Reconstitution Inflammatory Syndrome: IRIS IRIS: collection of inflammatory disorders Paradoxical worsening of preexisting infectious processes Assoc w/ immune recovery following ART initiation Risk Factors: CD4 and VL pre ART, short time between TB tx and ART initiation, but TB IRIS can occur at CD4 >200 Meintjes, Lancet ID, 2008 Immune Reconstitution Inflammatory Syndrome: IRIS IRIS: collection of inflammatory disorders Paradoxical worsening of preexisting infectious processes Assoc w/ immune recovery following ART initiation Risk Factors: CD4 and VL pre ART, short time between TB tx and ART initiation, but TB IRIS can occur at CD4 >200 Meintjes, Lancet ID,
13 TB IRIS: Clinical manifestations Pulmonary TB Sx: fever, malaise, weight loss, and worsening resp sx Worsening CXR: new parenchymal opacities and progressive intrathoracic lymph node Extrapulmonary TB Worsening lymphadenitis, new pleural effusions, intracranial tuberculomas, worsening of meningitis or radiculomyelopathy cold abscesses Meintjes, Lancet ID, 2008 TB IRIS: Treatment Continue ART unless life threatening Steroids RCT 4 wks prednisone vs. placebo for TB IRIS symptoms, improved CXR, hospitaliza on NSAIDS Recent trials: Empiric prednisone during 1 st 4 wks of ART risk of paradoxical TB IRIS by 30% Meintjes CROI 2017 Meintjes AIDS,
14 Question 3a 23 y/o Ethiopian F presents with weight, loss, fever, and cough. CXR shows RUL opacity. Sputum smear is neg. RIPE started due to concerns for PTB (NAAT return Mtb+). As part of her TB w/u she is tested for HIV and found to be positive w/ CD4 48. Which of the following are true? A. ART should be initiated within 2 weeks B. ART should be initiated after she has completed initial phase of TB treatment C. ART should be initiated after she has completed continuation phase of TB treatment D. TB treatment should be stopped until after she has initiated ART and her VL is undetectable Question 3b She initiates ART treatment and continues w/ RIPE. After 2 weeks she develops fever, and her CXR now shows worsening pulmonary infiltrates You should A. Stop ART B. Collect sputum looking for MDR TB and add moxifloxacin and amikacin while waiting C. Stop ART therapy and start prednisone D. Continue anti TB tx and ART, evaluate the patient for other infections, failed TB therapy and drug toxicity and consider starting prednisone 14
15 TB and HIV LTBI and HIV 15
16 Drug(s) Duration Comment Isoniazid 9 months Recommended Isoniazid + Rifapentine 3 months OK if NO ART or EFV or RAL based ART. Drug interactions : TAF, DOL Rifampin 4 months Drug interactions May required dose adjustment Rifabutin 4 months Drug interactions May required dose adjustment Rifampin + Pyrazinamide LTBI treatment in HIV+ 2 months Contraindicated Recent trials: 1 INH/RPT: not inferior to 9 INH Swindells CROI 2018 BRIEF TB/ACTG5279 INH pregnancy vs. postpartum : similar maternal safety, higher risk of fetal and pregnancy outcomes Gupta CROI 2018 IMPAACT 1078 Question 4 45 year old HIV+ male HCW well controlled on ART (FTC/TAF + DOL) recently converted his TST after a medical mission trip in Haiti. TB symptom screen and CXR are negative. He s heard about a new short course LTBI treatment that you only have to take once a week and wants to know what his options are. Based on CDC/ATS/DHHS guidelines you recommend: A. INH x 9 months (daily) B. RIF x 4 months (daily) C. RIF + PZA x 2 months (daily) D. INH + RPT x 3 months (weekly) 16
17 Shifting gears to shift/ TB and Solid Organ Transplant (SOT) TB risk x higher than general pop Incidence in low prevalence regions % Higher mortality 6 22% (vs <5% for TB in general US) Horne CID 2013, Aguado CID
18 TB and SOT: things to consider Reactivation of LTBI in setting of immunosuppression Recurrence of previously treated TB Drug drug interactions Baseline organ dysfunction Donor derived infections Unrecognized active TB Reactivation of LTBI in the graft Horne CID 2013 Aguado CID 2009 TB and SOT: risk factors Transplant related immunosuppression Standard TB risk factors Underlying medical condition Aguado CID
19 TB and SOT: risk factors Transplant related immunosuppression Standard TB risk factors Underlying medical condition Aguado CID 2009 TB and SOT: clinical manifestations Atypical presentations Non specific sx (fever, weight loss, night sweats) Extrapulmonary/disseminated more common Classic upper lobe infiltrate / cavities less likely Diagnostic delays Horne CID 2013, Aguado CID
20 TB and SOT: screening Recipient prior to transplant TST or IGRA However many SOT recipients who develop TB had neg TST/IGRA prior to transplant Chest imaging (CXR, +/ CT) Epidemiologic risk assessment Donors Living donors LTBI screening (and treatment) Deceased donors Moderate to high TB risk: imaging (consider CT) + AFB smear (+NAAT/Culture) donor with untreated LTBI, recent exposure, radiographic evidence of untreated TB > LTBI treatment for recipient Horne CID 2013, Aguado CID 2009 LTBI and SOT: treatment Timing: pre or post transplant? Horne CID
21 LTBI and SOT: treatment Choice of regimen INH RIF INH/RPT Best studied well tolerated preliver txp Shorter duration Shorter duration Need for further study: RBT, FLQ Longer duration Hepatotoxicity post txp P450 inducer immunosuppressive agents; rejection allograft loss Doesn t avoid INH adverse effects / rifamycin drug interactions Horne CID 2013, Aguado CID 2009 LTBI/TB treatment and SOT: important drug interactions Rifampicin reduces levels of many immunosuppressive agents Corticosteroids Calcineurin inhibitors: tacrolimus, cyclosporine mtors (mammalian target of rapamycins): rapamycin (sirolimus), everolimus Reduced levels immunosuppressant levels increase risk of graft rejection Need to increase dose of calcineurin inhibitors 3 5x, closely monitor levels Aguado CID
22 Question 5 49 y/o US born female underwent double lung transplant for bronchiolitis obliterans. Bronchoscopy POD 1 to ensure good anastomosis. BAL: AFB, Cx + MTB. Chest CT +small LUL nodules. Donor: 21 y/o Guatemalan immigrant with faint UL opacity, scattered midlung calcifications. Which of the following are true? A. Her immunosuppression medications should be decreased to reduce her risk of TB complications B. TB treatment should be delayed until she requires less immunosuppression Horne CID 2013, Winthrop Am J Transplant 2004 C. RIPE therapy should be initiated with reduced RIF dose to avoid drugdrug interactions with her immunosuppressants D. TB treatment should be initiated, and she will likely need an increase in her immunosuppressant dosing with close monitoring of drug levels to avoid graft rejection TB and Hematopoietic Stem Cell Transplant (HSCT) TB risk 10 40x higher than general population ~ 10X less common than among SOT (due to transient immunosuppression) Highest risk among allogenic transplants Primarily due to LTBI reactivation Aguado Microbio Spectrum
23 TB and Hematopoietic Stem Cell Transplant (HSCT) TB risk 10 40x higher than general population ~ 10X less common than among SOT (due to transient immunosuppression) Highest risk among allogenic transplants Primarily due to LTBI reactivation Donor derived infections appear insignificant Treatment for LTBI prior to conditioning therapy preferred Recommendations for screening and treatment of LTBI similar to SOT Aguado Microbio Spectrum 2016 Tomblyn Biol Blood Marrow Transplant 2009 TB and Biologics TNF alpha inhibitors Etanercept (soluble p75 receptor) Infliximab, adalimumab, golimumab, certolizumab (monoclonal antibodies) Il 1 inhibitors Anakinra B cell depletion Rituximab Anti CD20 T cell co stimulation Abatacept blockade 23
24 TB and Biologics TNF alpha inhibitors Etanercept (soluble p75 receptor) Infliximab, adalimumab, golimumab, certolizumab (monoclonal antibodies) Il 1 inhibitors Anakinra B cell depletion Rituximab Anti CD20 T cell co stimulation Abatacept blockade TNF alpha and TB Slide courtesy of Elizabeth Gilliams Gardam Lancet Infect Dis
25 TNF alpha and TB X TNF alpha blockade increases TB risk Slide courtesy of Elizabeth Gilliams Gardam Lancet Infect Dis TB risk and TNF alpha inhibitors Dixon Ann Rheum Dis
26 TB risk and TNF alpha inhibitors Slide courtesy of Kevin Winthrop Winthrop Nature Prac Rheum (in press) Winthrop Ann Rheum Disease 2013 TB risk and TNF alpha inhibitors: Risks are different by agent Infliximab and adalimumab suppress IFNγ production Depletion of CD8 cells that aid in killing intracellular TB Impaired granuloma formation Antibodies > receptor Monoclonal Ab Stronger affinity for TNFα Soluble receptor antagonist Slide courtesy of Elizabeth Gilliams Tracey, Pharm & Therapeutics 2018 Saliu JID 2006 Plessner JID
27 LTBI treatment and TNF alpha inhibitors Screen for LTBI prior to anti TNFα initiation Ideally receive 1 month LTBI treatment prior to anti TNFα Holding anti TNFα can be associated with IRISlike phenomenon Anti TNFα can be restarted within few months of TB tx initiation Cantini Autoimmunity Rev 2015 HIV/TB: Take home points HIV significantly increase risk of TB atypical presenta ons of PTB, EPTB and disseminated TB TB treatment similar to non HIV, but Daily Initial phase w/ RIPE, at least 3 x week Maintenance w/ IR Rifamycin based anti TB therapy is key May require ART dose adjustment Important to monitor for drug drug interactions and side effects IRIS typically managed w/ NSAIDS, steroids if severe Concerns for TB IRIS should not delay HAART initiation 27
28 TB and other immunosuppressive states: Take home points Important to screen for LTBI in SOT/HSCT recipients Ideally before transplant TB risk primarily due to LTBI reactivation, but can be donor derived in SOT Rifampicin reduces levels of many immunosuppressant agents used in SOT/HSCT Increases risk of graft rejection Often requires increased dose of immunosuppressants TNF alpha inhibitors significantly increase risk of TB Ideally initiate LTBI treatment before anti TNFα initiation Stopping anti TNFα assoc with IRIS, can restart within few months of TB tx Resources Panel on Opportunistic Infections in HIV Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV infected adults and adolescents: Updated September 22, and adolescent oi prevention andtreatment guidelines/325/tb CDC. Managing Drug Interactions in the Treatment of HIV Related Tuberculosis CDC. Reported Tuberculosis in the United States, Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children opi/diagnosis oftuberculosis in adults and children.pdf WHO. Global Tuberculosis Report Latent TB infection. National HIV curriculum. September occurring conditions/latent tuberculosis/core concept/all Horne DJ, Narita M, Spitters CL, et al. Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis Nov;57(10):
29 Acknowledgements Robert Harrington David Horne Masa Narita Bijan Ghassemieh Kevin Winthrop Elizabeth Gilliams Additional references Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med Jul 19;345(3): Geldmacher C, Zumla A, Hoelscher M. Interaction between HIV and Mycobacterium tuberculosis: HIV 1 induced CD4 T cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS May;7(3): Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol. 2011;2011 Parimon T, Spitters CE, Muangman N, et al. Unexpected pulmonary involvement in extrapulmonary tuberculosis patients. Chest Sep;134(3): Lawn SD, Meintjes G, McIlleron H, et al. Management of HIV associated tuberculosis in resource limited settings: a state of the art review. BMC Med Dec 2;11:253. ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med Oct 15;174(8): Meintjes G, Lawn SD, Scano F, et al. Tuberculosis associated immune reconstitution inflammatory syndrome: case definitions for use in resourcelimited settings. Lancet Infect Dis Aug;8(8): Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo controlled trial of prednisone for paradoxical tuberculosis associated immune reconstitution inflammatory syndrome. AIDS Sep 24;24(15): Horne DJ, Narita M, Spitters CL, et al. Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis Nov;57(10): Aguado JM, Silva JT, Samanta P, Singh N. Tuberculosis and Transplantation. Microbiol Spectr Nov;4(6). Aguado JM, Torre Cisneros J, Fortún J, et al. Tuberculosis in solid organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis May 1;48(9): Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant Oct;15(10): Gardam MA, Keystone EC, Menzies R, et al. Anti tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis Mar;3(3): Dixon WG, Hyrich KL, Watson KD, et al. Drug specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis Mar;69(3): Cantini F, Nannini C, Niccoli L, et al. SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev Jun;14(6): Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis Jan;72(1):
30 HIV/TB 10% new TB cases HIV+ WHO 2016, 2017 Global TB/HIV epidemiology: over time 10.4 million 1.3 million 374, million ~10% new cases HIV+ ~1/4 TB deaths HIV+ WHO
31 Global TB Epidemiology WHO 2017 Global TB/HIV Epidemiology TB and HIV are co epidemics WHO
32 US TB Epidemiology Reported Tuberculosis (TB) Cases United States, * 30,000 No. of Cases 25,000 20,000 15,000 10,000 5, Year CDC 2017 US TB Epidemiology Reported Tuberculosis (TB) Cases United States, * 30,000 No. of Cases 25,000 20,000 15,000 10,000 5,000 0 HIV epidemic contributed to TB resurgence in late 80s Year CDC
33 70 US TB/HIV Epidemiology Estimated HIV Coinfection in Persons with TB, % Coinfection Year All ages Ages yrs CDC US TB/HIV Epidemiology Estimated HIV Coinfection in Persons with TB, % Coinfection Proportion of TB cases with HIV decreasing Year All ages Ages yrs CDC
34 US TB/HIV Epidemiology global = local Estimated HIV/TB Coinfection cases US vs Foreign born, N=3145 # Cases N=500 N=273 N= Year Foreign Born US Born CDC 2017 # Cases US TB/HIV Epidemiology global = local Estimated HIV/TB Coinfection cases US vs Foreign born, N=3145 N= Year HIV+ TB cases among foreign born now exceed US born Foreign Born US Born N=273 N=230 CDC
35 Question A Which of the following is true? A. Globally, TB incidence is increasing B. In the US, TB incidence is increasing C. Globally, incidence of TB among HIV+ is increasing D. In the US, number of new TB cases with HIV who are foreign born exceeds that among US born E. In the US, proportion of new TB cases with HIV is increasing Question B 25 y/o woman from Eritrea, HIV+ not yet on ART with CD4 100 presents with 2 3 month history of enlarging cervical lymph node, fever and weight loss. She denies obvious cough. You are concerned for extrapulmonary TB. Which of the following should be part of the work up for extrapulmonary TB in this HIV+ patient? A. Lymph node biopsy including AFB smear and culture B. CXR C. Sputum AFB smear and culture D. All of the above E. A & B 35
36 Question C 42 y/o HIV+ homeless man is diagnosed with pulmonary TB and started on RIPE. He has a history of significant mental health issues worsened on Atripla (efavirenz + truvada). Because of this (and in line with current US HIV guidelines) you had previously switched his efavirenz to dolutegravir last year. At his next follow up visit, his viral load (previously undetectable) is now >1000. Assuming he has no new HIV resistance, and he has been adherent to both his ART and anti TB therapy, you should A. Decrease his dose of rifampin B. Increase his dose of dolutegravir from 50 mg PO QDAY to BID C. Consider switching rifampin for rifabutin D. B or C 36
HIV/TB. Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease. TB Clinical Intensive Seattle, WA June 16-17, 2016
HIV/TB Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease TB Clinical Intensive Seattle, WA June 16-17, 2016 Roadmap for today s talk HIV/TB Epidemiology Global US
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationApproach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD
Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB Physician Advisory Board Cooper Univ. Hospital EIP Program TB and HIV
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationTuberculosis: update 2013
Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationTB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:
TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationCLINICAL VIGNETTE: Patient 1. Approach to Co-infection with TB and HIV: TB and HIV Co-infection: Some Resources. Goals and Objectives
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb http://www.umdnj.edu/globaltb/coretbresources.htm Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J.
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationClinical Vignette: Patient 1. Approach to Co-infection with TB. TB and HIV Co-infection: Some Resources. Objectives.
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb AETC Natl Resource Center: http://www.aidsetc.org Approach to Co-infection with TB and HIV: 2012 Henry Fraimow, MD Consultant, Southern N.J.
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationHIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationImmune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela
Immune Reconstitution Inflammatory Syndrome Dr. Lesego Mawela TOPICS FOR DISCUSSION IRIS Case Epidermiology Pathogenesis of IRIS Risk factors for IRIS Epidemiology of IRIS Health system burden of IRIS
More informationTuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009
TB in the Correctional Setting Collinsville, Illinois April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD
More informationDiagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015
Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationCLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationTB in the Correctional Setting Florence, Arizona October 7, 2014
TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures
More informationMy heart is racing. Managing Complex Cases. Case 1. Case 1
Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationTB and Co-Morbidities Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 TB and Co-Morbidities Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More information1/18/2011. Handling TB and HIV. Fargo, North Dakota September 15-16, Treatment of TB in the HIV Co-Infected Patient
1/18/2011 Handling TB and HIV Co-Infection Fargo, North Dakota September 15-16, 2010 Treatment of TB in the HIV Co-Infected Patient Dean Tsukayama, MD September 15, 2010 1 Co-infection with TB and HIV
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationTB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationMDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationTB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationOutline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?
Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs
More informationDiagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationHIV and TB coinfection: Updates. Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
HIV and TB coinfection: Updates Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University Learning objectives Identify the optimal timing of antiretroviral therapy in patients
More informationPediatric TB Intensive Houston, Texas October 14, 2013
Pediatric TB Intensive Houston, Texas October 14, 2013 Diagnosis and Management of Tuberculosis in Adolescents Andrea T. Cruz, MD, MPH Sections of Infectious Diseases & Emergency Medicine October 14, 2013
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTreatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1
Treatment of Tuberculosis Some Highlights of Most Recent Update Treatment of Tuberculosis Disease Germaine Jacquette, MD Physician Specialist NJMS Global Tuberculosis Institute September 15, 2010 The provider
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationTB and HIV co-infection including IRIS
TB and HIV co-infection including IRIS Richard Lessells SAHCS Conference 2018 Clinical scenario 1 36-year-old male Presents with cough, fever & weight loss HIV test positive (new diagnosis) Sputum Xpert
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More information"Sterilization of TB disease in
11/1/1 "Sterilization of TB disease in mice " Jacques Grosset Pharmacodynamics of daily rifapentine and rifampin in mice Free rifam mycin Concentrati ion/mic 1 1 Rifapentine (1mg/kg) Free rifam mycin Concentrati
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2013 Case 1: 52 y/o male Born in the Pacific Islands; some travel in
More informationLTBI Treatment in non HIV immunosuppressed patients. Richard Zuckerman, MD, MPH, FIDSA
LTBI Treatment in non HIV immunosuppressed patients Richard Zuckerman, MD, MPH, FIDSA Disclosures AiCuris, Medpace DSMB for acyclovir-resistant HSV Case 67 yo M with cirrhosis due to NASH, hepatocellular
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationCase Presentations Part 2
Case Presentations Part 2 Connie A. Haley, MD MPH University of Florida, Infectious Diseases and Global Medicine Megan Ninneman, PA Jackson Memorial Hospital, Miami FL Objectives Demonstrate the ability
More informationDifference of opinion? Michelle Moorhouse 24 Sep 2014
Difference of opinion? Michelle Moorhouse 24 Sep 2014 Meet NN 52 years, female Nurse in pre-art clinic Referred Feb 2012 by dermatologist History of severe reactions to ART Erythema and bullous eruptions
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationTuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013
Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case
More informationNurse Case Management Phoenix, Arizona February 20-22, 2008
Nurse Case Management Phoenix, Arizona February 20-22, 2008 TB/HIV: Managing the Co-Infected Patient Adriana Vasquez, MD February 21, 2008 HIV Treatment Guidelines DHHS December 1,2007 TB/HIV Managing
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationTuberculosis in AIDS Patients. Chien-Ching Hung Division of Infectious Diseases Department of Internal Medicine National Taiwan University Hospital
Tuberculosis in AIDS Patients Chien-Ching Hung Division of Infectious Diseases Department of Internal Medicine National Taiwan University Hospital Topics Epidemiology of TB in the era of HIV epidemic Impact
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationStandard TB Treatment
Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationTuberculosis in Non-HIV Infected Immunosuppresed Hosts. TNFα inhibitors and beyond
Tuberculosis in Non-HIV Infected Immunosuppresed Hosts TNFα inhibitors and beyond David E. Griffith, MD Assistant Medical Director Heartland National TB Center Professor of Medicine University of Texas
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationPreventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More information